This study aimed to determine the molecular mechanism by which the oncogenic micoRNA-21 (miR-21) functions in bladder cancer. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis showed that the expression of miR-21 considerably increased in primary cancer tissue compared with that in the paired adjacent noncancerous tissue and that in normal bladder mucosa. Knockdown of miR-21 by using antisense oligonucleotide significantly suppressed the proliferation and migration of bladder cancer cells (J82 and RT112). Mechanism studies showed that downregulation of miR-21 resulted in cell cycle arrest at the G1 phase and upregulation of the tumor suppressor PTEN (phosphatase and tensin homologue) and p53 phosphorylation at Ser46. The p53 phosphorylation at Ser15 and the whole level of p53 acetylation remained unchanged in response to miR-21 knockdown. MicroRNA-21 regulates proliferation and migration of bladder cancer cells and cross talk with PTEN and p53 in bladder cancer.
Get full access to this article
View all access options for this article.
References
1.
AdamsB.D., KasinskiA.L., and SlackF.J. (2014). Aberrant regulation and function of microRNAs in cancer. Curr Biol, 24, R762–r776.
2.
AmeresS.L., and ZamoreP.D. (2013). Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol, 14, 475–488.
3.
BuscagliaL.E., and LiY. (2011). Apoptosis and the target genes of microRNA-21. Chin J Cancer, 30, 371–380.
4.
CattoJ.W., MiahS., OwenH.C., BryantH., MyersK., DudziecE., LarreS., MiloM., RehmanI., RosarioD.J., et al. (2009). Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res, 69, 8472–8481.
5.
ChanJ.A., KrichevskyA.M., and KosikK.S. (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 65, 6029–6033.
6.
ChenC., RidzonD.A., BroomerA.J., ZhouZ., LeeD.H., NguyenJ.T., BarbisinM., XuN.L., MahuvakarV.R., AndersenM.R., et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33, e179.
7.
DashzevegN., TairaN., LuZ.G., KimuraJ., and YoshidaK. (2014). Palmdelphin, a novel target of p53 with Ser46 phosphorylation, controls cell death in response to DNA damage. Cell Death Dis, 5, e1221.
8.
DeHartC.J., ChahalJ.S., FlintS.J., and PerlmanD.H. (2014). Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol Cell Proteomics, 13, 1–17.
9.
DyrskjotL., OstenfeldM.S., BramsenJ.B., SilahtarogluA.N., LamyP., RamanathanR., FristrupN., JensenJ.L., AndersenC.L., ZiegerK., et al. (2009). Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res, 69, 4851–4860.
10.
HillR., KalathurR.K., CallejasS., ColacoL., BrandaoR., SereldeB., CebriaA., Blanco-AparicioC., PastorJ., FutschikM., et al. (2014). A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res, 16, 482.
11.
HollanderM.C., BlumenthalG.M., and DennisP.A. (2011). PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer, 11, 289–301.
12.
JemalA., SiegelR., WardE., HaoY., XuJ., and ThunM.J. (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225–249.
13.
KumarswamyR., VolkmannI., and ThumT. (2011). Regulation and function of miRNA-21 in health and disease. RNA Biol, 8, 706–713.
14.
LingH., FabbriM., and CalinG.A. (2013). MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov, 12, 847–865.
15.
LougheryJ., CoxM., SmithL.M., and MeekD.W. (2014). Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res, 42, 7666–7680.
16.
MakA.S. (2014). p53 in cell invasion, podosomes, and invadopodia. Cell Adh Migr, 8, 205–214.
17.
MengF., HensonR., Wehbe-JanekH., GhoshalK., JacobS.T., and PatelT. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647–658.
18.
MullerP.A., and VousdenK.H. (2014). Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer cell, 25, 304–317.
19.
MullerP.A., VousdenK.H., and NormanJ.C. (2011). p53 and its mutants in tumor cell migration and invasion. J Cell Biol, 192, 209–218.
20.
NeelyL.A., Rieger-ChristK.M., NetoB.S., EroshkinA., GarverJ., PatelS., PhungN.A., McLaughlinS., LibertinoJ.A., WhitneyD., et al. (2010). A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol, 28, 39–48.
21.
RufiniA., TucciP., CelardoI., and MelinoG. (2013). Senescence and aging: the critical roles of p53. Oncogene, 32, 5129–5143.
22.
SartiniD., MuzzonigroG., MilaneseG., PozziV., ViciA., MorgantiS., RossiV., MazzucchelliR., MontironiR., and EmanuelliM. (2013). Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys, 65, 473–483.
23.
SerontE., PintoA., BouzinC., BertrandL., MachielsJ.P., and FeronO. (2013). PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer, 109, 1586–1592.
24.
ShaoJ., GuM., XuZ., HuQ., and QianL. (2007). Polymorphisms of the DNA gene XPD and risk of bladder cancer in a Southeastern Chinese population. Cancer Genet Cytogenet, 177, 30–36.
25.
SmeenkL., van HeeringenS.J., KoeppelM., GilbertB., Janssen-MegensE., StunnenbergH.G., and LohrumM. (2011). Role of p53 serine 46 in p53 target gene regulation. PLoS One, 6, e17574.
26.
SongB., WangC., LiuJ., WangX., LvL., WeiL., XieL., ZhengY., and SongX. (2010). MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res, 29, 29.
27.
SongM.S., SalmenaL., and PandolfiP.P. (2012). The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol, 13, 283–296.
28.
TangY., ZhaoW., ChenY., ZhaoY., and GuW. (2008). Acetylation is indispensable for p53 activation. Cell, 133, 612–626.
29.
WangY., GaoX., WeiF., ZhangX., YuJ., ZhaoH., SunQ., YanF., YanC., LiH., et al. (2014). Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene, 533, 389–397.
30.
XiongB., ChengY., MaL., and ZhangC. (2013). MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol, 42, 219–228.
31.
XuL.F., WuZ.P., ChenY., ZhuQ.S., HamidiS., and NavabR. (2014). MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS One, 9, e103698.
